EMERALD-3: Is STRIDE-Based TACE Combination Therapy a Breakthrough for Embolization-Eligible Unresectable HCC? | Synapse

⌘+K

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants (pts) with unresectable embolization-eligible hepatocellular carcinoma (eeHCC).RCT · 2026 · 3 citations
2Transarterial chemoembolisation-based combination therapy as a potential new standard for intermediate-stage hepatocellular carcinoma in the targeted immunotherapy eraOriginal Research · 2026 · 1 citations
3Outcomes by transarterial chemoembolization (TACE) modality from participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D)+bevacizumab (B)+TACE and placebos (PBO)+TACE: EMERALD-1 subgroup analysis2025
4Integrating Combination Therapy and Smart Embolic Materials to Overcome the Therapeutic Ceiling of Transarterial Chemoembolization in Hepatocellular CarcinomaClinical Trial · 2026
5Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Recent Progression and PerspectiveOriginal Research · 2013 · 14 citations

Transarterial chemoembolization combined with immunotherapy and targeted therapy as first-line treatment for unresectable and non-metastatic hepatocellular carcinoma: a meta-analysis of phase III trials2025
Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D)+bevacizumab (B)+transarterial chemoembolization (TACE) and placebos+TACE: EMERALD-1 post hoc analysis2025
Temperature-sensitive liquid embolic agent transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for BCLC Stage B/C hepatocellular carcinoma: a multicenter real-world study and spatial transcriptomics profiling (CHANCE 2515)2026
A radio-transcriptome signature for nodule-level prediction of response to atezolizumab plus bevacizumab in hepatocellular carcinomaLiver Cancer · 2026
2026 International Expert Consensus Recommendations on Image-Guided Ablation for Colorectal Liver MetastasesLiver Cancer · 2026

More from Liver Cancer